Core Viewpoint - The company, Asia-Pacific Pharmaceutical (002370.SZ), has participated in the continuation procurement organized by the National Organization for Drug Procurement, with 13 products, including injectable Cefmetazole Sodium and Febuxostat tablets, proposed for selection in the continuation procurement process [1] Group 1: Procurement Details - The continuation procurement involves products from the first to eighth batches of the national organized procurement agreements that have expired [1] - The agreed procurement volume for each product will be based on the demand reported by medical institutions, with the selection price gradient determining the volume ratio [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this continuation procurement during the procurement period, ensuring the completion of the agreed procurement volume [1] - If the company signs procurement contracts and implements them, it will further expand the sales of related products, enhance market share, and improve brand influence, positively impacting future operating performance [1]

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced that its subsidiary, Jincheng Jinsu, received approval from the National Medical Products Administration for a supplemental application for injectable Cefmetazole Sodium in various specifications [1] - The approved specifications include 0.25g, 1.0g, and 2.0g, and the drug approval number has been issued with a validity period of 18 months [1] - According to the data from Minet, the sales revenue of injectable Cefmetazole Sodium in domestic public medical institutions is projected to be 1.337 billion RMB, 1.277 billion RMB, and 1.334 billion RMB for the years 2022, 2023, and 2024 respectively [1]